Deregulated apoptosis is a hallmark of cancer, and the B-cell lymphoma-2 (Bcl-2) family of proteins is pivotal to mediating the intrinsic pathway of this process. Recent advances have yielded both pan-Bcl-2 small molecule inhibitors (SMIs) that inhibit both the Bcl-2 and the Mcl-1 arm of the Bcl-2 family anti-apoptotic proteins, as well as selective SMIs to differentially target the two arms. O...

The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the ...

Introduction. Trastuzumab is the first known anti-HER2 agent, which revolutionized treatment of one most common cancer types – breast cancer. Despite trastuzumab being approved long time ago, further improvement related analytical methods remains relevant primarily due to emergence new biosimilars. For instance, immunogenicity adverse reaction usually associated with biological drugs, can still...

Pluronic based nano-particulate systems are innovative platforms for delivery of anti-cancer agents. These systems due to their pharmacological properties and suitable physicochemical characteristics are great opportunity for development cancer therapeutics. This mini-review tries to provide a more detailed overview on the currently available pluronic based drug delivery systems. In the section...